financetom
Business
financetom
/
Business
/
Daimler Truck eyes half of Europe sales from EVs in 2030
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Daimler Truck eyes half of Europe sales from EVs in 2030
Sep 16, 2024 12:38 PM

HANOVER, Germany (Reuters) - Daimler Truck, one of the world's biggest commercial vehicle makers, aims for half of its European sales to come from electric trucks in 2030, the head of its Mercedes-Benz Trucks unit, Karin Radstrom, said on Monday.

Radstrom, who is due to take the helm of the whole group next month, seeks to sell as many as 30,000 electric trucks, or half of Daimler's s total vehicle sales in Europe, by the end of the decade.

"Hopefully we'll be so good that we can do even more," she said at a press conference during the IAA Transportation trade fair in Hanover.

Daimler Truck will start producing its first fully-electric heavy truck Mercedes-Benz eActros 600 in November this year and has already received 2,000 orders for it.

Its outgoing CEO Martin Daum earlier on Monday said he sees no easing on the European truck market in the first half of 2025.

The group faces subdued demand after chips and other parts shortages in the wake of the COVID-19 pandemic pushed up production costs.

The trucking industry also faces challenges to reduce pollution from commercial vehicles, while logistic firms, their main clients, are unwilling to pay more for electric trucks as the charging infrastructure is still far from complete.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Nuvectis Pharma Q3 net loss widens
Nuvectis Pharma Q3 net loss widens
Nov 4, 2025
Overview * Nuvectis Q3 net loss widens to $7.5 mln, driven by milestone and study costs * Cash position improves to $35.4 mln, supported by public offering and ATM facility * NXP900 Phase 1b program initiated, showcasing therapeutic potential in advanced cancers Outlook * Cash runway expected to support operations into 3Q-2027 Result Drivers * Research and development expenses were...
BRIEF-Evoke Pharma Enters Into Definitive Agreement To Be Acquired By QOL Medical
BRIEF-Evoke Pharma Enters Into Definitive Agreement To Be Acquired By QOL Medical
Nov 4, 2025
Nov 4 (Reuters) - Evoke Pharma Inc ( EVOK ): * EVOKE PHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY QOL MEDICAL * EVOKE PHARMA INC ( EVOK ): PROPOSED DEAL FOR FOR $11.00 PER SHARE IN CASH AT CLOSING Source text: Further company coverage: ...
Hillman Q3 net sales rise 8%, beat estimates
Hillman Q3 net sales rise 8%, beat estimates
Nov 4, 2025
Overview * Hillman Q3 2025 net sales rise 8% to record $424.9 mln, beating analyst expectations * Adjusted EPS for Q3 2025 beats consensus, reaching $0.22 per share * Company repurchased 325.6 thousand shares, totaling $3.2 mln Outlook * Hillman maintains FY 2025 net sales guidance at $1.535 to $1.575 bln * Company raises FY 2025 adjusted EBITDA guidance to...
Wingstop Q3 system-wide sales rise 10%, helped by new restaurants
Wingstop Q3 system-wide sales rise 10%, helped by new restaurants
Nov 4, 2025
Overview * Wingstop ( WING ) fiscal Q3 system-wide sales rise 10% to $1.4 bln * Adjusted EBITDA for fiscal Q3 grows 18.6% to $63.7 mln, highest quarter on record * Company opened 114 net new restaurants, achieving 19.3% net new unit growth Outlook * Wingstop ( WING ) revises 2025 domestic same store sales growth to decline 3%-4% *...
Copyright 2023-2026 - www.financetom.com All Rights Reserved